Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Non-Hodgkin 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Rituximab 4Etoposide 4Whole-Body Irradiation 2Gemcitabine 2Cyclophosphamide 2umbralisib 1ublituximab 1rasburicase 1pegfilgrastim 1fludarabine phosphate 1fludarabine 1epratuzumab 1aldesleukin 1Trimethoprim, Sulfamethoxazole Drug Combination 1Thiotepa 1Radioimmunodetection 1Prednisone 1Oxaliplatin 1Nivolumab 1Melphalan 1Leucovorin 1Lenalidomide 1Immunoglobulins, Intravenous 1Hizentra 1Filgrastim 1Doxorubicin 1Cytarabine 1Ciprofloxacin 1Carboplatin 1Busulfan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Lymphoma, Non-Hodgkin × Hizentra × Clear all
NCT03211065 2021-04-19

Humoral Immunodeficiency With Rituximab and Therapy With Subcutaneous Ig

Rochester General Hospital

Phase 2/3 Completed
16 enrolled
Lymphoid

Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡